Azumino, Japan

Yukihiko Hotei



Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Hotaka-machi, JP (1999)
  • Nagano, JP (2007)
  • Azumino, JP (2016 - 2017)

Company Filing History:


Years Active: 1999-2017

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Yukihiko Hotei

Introduction

Yukihiko Hotei is a notable inventor based in Azumino, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of medications aimed at treating constipation. With a total of 4 patents to his name, Hotei's work has garnered attention in the medical community.

Latest Patents

One of Hotei's latest patents is focused on pyrazole derivatives and their use for medical purposes. This invention provides pyrazole derivatives that are particularly useful for the prevention or treatment of constipation. The active ingredient in these pharmaceuticals is 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide, or a pharmaceutically acceptable salt thereof. These pharmaceuticals are designed to increase the frequency of bowel movements, making them effective for those suffering from constipation.

Career Highlights

Yukihiko Hotei is currently associated with Kissei Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in developing new treatments that address common health issues.

Collaborations

Hotei has collaborated with several professionals in his field, including Hidetoshi Isawa and Masayuki Isaji. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Yukihiko Hotei's contributions to the pharmaceutical industry, particularly through his innovative patents, highlight his commitment to improving medical treatments for constipation. His work continues to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…